Assessment of regional changes in skeletal metabolism following 3 and 18 months of teriparatide treatment

Journal of Bone and Mineral Research

Volumn 25, Issue 5, 2010, Pages 960-967

  Moore, Amelia E B ^a   Blake, Glen M ^a   Taylor, Kathleen A ^b   Rana, Asad E ^b   Wong, Mayme ^b   Chen, Peiqi ^b   Fogelman, Ignac ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Lilly USA   (United States)

Author keywords

Bone remodeling; Bone turnover markers; Osteoporosis; Radionuclide bone scan; Teriparatide

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CALCIUM; MEDRONATE TECHNETIUM TC 99M; PARATHYROID HORMONE[1-34]; VITAMIN D;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARM; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; BONE BLOOD FLOW; BONE DENSITY; BONE METABOLISM; BONE PAIN; BONE SCINTISCANNING; BONE TURNOVER; CALVARIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG EFFECT; DRUG RETENTION; DRUG UPTAKE; FEMALE; FRACTURE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LEG; MANDIBLE; OSTEOBLAST; PELVIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; SPINE; TREATMENT DURATION; ULTRAFILTRATION; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE AND BONES; BONE DENSITY; COLLAGEN TYPE I; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M MEDRONATE; TERIPARATIDE;

EID: 77953482810     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.091108     Document Type: Article

References (35)

1. Lindsay R, Nieves J, Formica C, et al. Randomised, controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997;350:550-555. (Pubitemid 27348431)
2. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
3. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9-17. (Pubitemid 36008334)
4. Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005;16:510-516.
5. Bilezikian JP. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep. 2008;6:24-30.
6. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003;18:1932-1941.
7. McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005;165:1762-1768. (Pubitemid 41138965)
8. Arlot M, Meunier PJ, Boivin G, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res. 2005;20:1244-1253. (Pubitemid 40863814)
9. Chen P, Miller PD, Recker R, et al. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res. 2007;22:1173-1180. (Pubitemid 351339699)
10. Ma YL, Zeng Q, Donley DW, et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res. 2006;21:855-864. (Pubitemid 43787992)
11. Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005;20:962-970. (Pubitemid 40712820)
12. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006;21:1785-1790. (Pubitemid 46141234)
13. Subramanian G, McAfee JG, Blair RJ, Kallfelz FA, Thomas FD. Technetium-99m-methylene diphosphonate-a superior agent for skeletal imaging: comparison with other technetium complexes. J Nucl Med. 1975;16:744-755.
14. Collier BD, Fogelman I, Rosenthall L, eds. Skeletal Nuclear Medicine. St. Louis, MO, USA: Mosby; 1996.
15. Gnanasegaran G, Cook GJ, Fogelman I. Radionuclide scintigraphy in metabolic bone disease In: Rosen CJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Washington, DC, USA: American Society for Bone and Mineral Research; 2008:166-169.
16. Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001;31:28-49. (Pubitemid 32060651)
17. Park-Holohan SJ, Blake GM, Fogelman I. Quantitative studies of bone using 18F-fluoride and 99mTc-methylene diphosphonate: evaluation of renal and whole-blood kinetics. Nucl Med Commun. 2001;22:1037-1044. (Pubitemid 32783456)
18. 99mTc-methylene diphosphonate skeletal plasma clearance. J Nucl Med. 2006;47:581-586.
19. Moore AE, Blake GM, Fogelman I. Quantitative measurements of bone remodeling using 99mTc-methylene diphosphonate bone scans and blood sampling. J Nucl Med. 2008;49:375-382. (Pubitemid 351355202)
20. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series No. 843, Geneva, Switzerland, 1994.
21. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8:468-489. (Pubitemid 28486716)
22. Patel R, Blake GM, Rymer J, Fogelman I. Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women. Osteoporos Int. 2000;11:68-75. (Pubitemid 30099513)
23. Jonsson L, Ljungberg M, Strand SE. Evaluation of accuracy in activity calculations for the conjugate view method from Monte Carlo simulated scintillation camera images using experimental data in an anthropomorphic phantom. J Nucl Med. 2005;46:1679-1686. (Pubitemid 46211591)
24. Moore AE, Hain SF, Blake GM, Fogelman I. Validation of ultrafiltration as a method of measuring free 99mTc-MDP. J Nucl Med. 2003;44:891-897. (Pubitemid 39663399)
25. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7.
26. Peters AM. Graphical analysis of dynamic data: the Patlak-Rutland plot. Nucl Med Commun. 1994;15:669-672.
27. Grewal GS, Blake GM. Reference data for 51Cr-EDTA measurements of the glomerular filtration rate derived from live kidney donors. Nucl Med Commun. 2005;26:61-65.
28. Lim GC, Wafa WS, Moses AM. Increased focal uptake of Tc-99m labelled MDP on bone scan suggestive of hyperostosis frontalis interna in a patient being treated with teriparatide. J Bone Mineral Res. 2005;20 [Suppl 1]: S174.
29. Sy WM. Bone scan in primary hyperparathyroidism. J Nucl Med. 1974;15:1089-1091.
30. Hain SF, Fogelman I. Nuclear medicine studies in metabolic bone disease. Semin Musculoskelet Radiol. 2002;6:323-329. (Pubitemid 36055636)
31. Nishida H, Kaida H, Ishibashi M, et al. Usefulness of bone uptake ratio of bone scintigraphy in hemodialysis patients. Ann Nucl Med. 2005;19:91-94. (Pubitemid 40745690)
32. Messa C, Goodman WG, Hoh CK, et al. Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol Metab. 1993;77:949-955.
33. Fogelman I, Bessent RG, Turner JG, Citrin DL, Boyle IT, Greig WR. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med. 1978;19:270-275. (Pubitemid 8305106)
34. Brenner W, Bohuslavizki KH, Sieweke N, Tinnemeyer S, Clausen M, Henze E. Quantification of diphosphonate uptake based on conventional bone scanning. Eur J Nucl Med. 1997;24:1284-1290. (Pubitemid 27477622)
35. Scillitani A, Dicembrino F, Chiodini I, et al. Global skeletal uptake of 99mTc-methylene diphosphonate (GSU) in patients affected by endocrine diseases: comparison with biochemical markers of bone turnover. Osteoporos Int. 2002;13:829-834. (Pubitemid 36336729)